INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Triple-negative Breast Cancer
Interventions: BIOLOGICAL: Pelareorep|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|BIOLOGICAL: Retifanlimab
Sponsor: Mridula George, MD
Collaborators: Incyte Corporation|Oncolytics Biotech|National Cancer Institute (NCI)